These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727 [TBL] [Abstract][Full Text] [Related]
4. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations. Singer CF; Balmaña J; Bürki N; Delaloge S; Filieri ME; Gerdes AM; Grindedal EM; Han S; Johansson O; Kaufman B; Krajc M; Loman N; Olah E; Paluch-Shimon S; Plavetic ND; Pohlodek K; Rhiem K; Teixeira M; Evans DG Eur J Cancer; 2019 Jan; 106():54-60. PubMed ID: 30471648 [TBL] [Abstract][Full Text] [Related]
5. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754 [TBL] [Abstract][Full Text] [Related]
6. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585 [TBL] [Abstract][Full Text] [Related]
7. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland. Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C; Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men. Chandrasekar T; Gross L; Gomella LG; Hegarty SE; Leong JY; Giri VN Eur Urol Oncol; 2020 Jun; 3(3):291-297. PubMed ID: 31278035 [TBL] [Abstract][Full Text] [Related]
10. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds. Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920 [TBL] [Abstract][Full Text] [Related]
11. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing. Giri VN; Hartman R; Pritzlaff M; Horton C; Keith SW JCO Precis Oncol; 2022 May; 6(1):e2200234. PubMed ID: 35666082 [TBL] [Abstract][Full Text] [Related]
12. Genomic Markers in Prostate Cancer Decision Making. Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398 [TBL] [Abstract][Full Text] [Related]
13. Bringing Prostate Cancer Germline Genetics into Clinical Practice. Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411 [TBL] [Abstract][Full Text] [Related]
14. Genetic testing for hereditary prostate cancer: Current status and limitations. Zhen JT; Syed J; Nguyen KA; Leapman MS; Agarwal N; Brierley K; Llor X; Hofstatter E; Shuch B Cancer; 2018 Aug; 124(15):3105-3117. PubMed ID: 29669169 [TBL] [Abstract][Full Text] [Related]
15. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine. Marino F; Totaro A; Gandi C; Bientinesi R; Moretto S; Gavi F; Pierconti F; Iacovelli R; Bassi P; Sacco E Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):655-664. PubMed ID: 36434163 [TBL] [Abstract][Full Text] [Related]
16. Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort. Wei J; Yang W; Shi Z; Lu L; Wang Q; Resurreccion WK; Engelmann V; Zheng SL; Hulick PJ; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J Prostate; 2021 Sep; 81(13):1002-1008. PubMed ID: 34254341 [TBL] [Abstract][Full Text] [Related]
17. Prevention and Screening in Hereditary Breast and Ovarian Cancer. Zeichner SB; Stanislaw C; Meisel JL Oncology (Williston Park); 2016 Oct; 30(10):896-904. PubMed ID: 27753056 [TBL] [Abstract][Full Text] [Related]
18. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392 [TBL] [Abstract][Full Text] [Related]
19. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. Brandão A; Paulo P; Teixeira MR Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708810 [TBL] [Abstract][Full Text] [Related]
20. Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Giri VN; Obeid E; Hegarty SE; Gross L; Bealin L; Hyatt C; Fang CY; Leader A Prostate; 2018 Sep; 78(12):879-888. PubMed ID: 29655297 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]